In a prespecified 3-year analysis of the KEN SHE trial, single-dose HPV vaccination was shown to be well tolerated and provided durable protection against cervical HPV infection in Kenyan women aged 15–20 years.
- Ruanne V. Barnabas
- Elizabeth R. Brown
- Torin T. Schaafsma